Identification of the Novel Role of CD24 as an Oncogenesis Regulator and Therapeutic Target for Triple Negative Breast Cancer

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0292
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Identification of Novel Therapeutic Targets for Triple-Negative Breast Cancer

2012English

Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer

Genes and Cancer
Cancer ResearchGenetics
2012English

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer

Scientific Reports
Multidisciplinary
2019English

Mesothelin, a Novel Immunotherapy Target for Triple Negative Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

ICAM-1 as a Molecular Target for Triple Negative Breast Cancer

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2014English

Therapeutic Advances and New Directions for Triple-Negative Breast Cancer

Breast Care
SurgeryOncology
2017English

Therapeutic Landscape in Mutational Triple Negative Breast Cancer

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2018English

Identification of New Prognostic Biomarkers for Triple Negative Breast Cancer

English

Role of Immunotherapy in Triple-Negative Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy